(Q30477000)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Thorsten Lauter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Peter H Kraus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Horst Przuntek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Juergen E Andrich

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

28 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?

17 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Cortical reflex myoclonus in adult onset Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Valproate and neuroprotection

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Cortical Myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Myoclonus and Huntington's chorea: Description of a case

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Valproate: an updated review.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Myoclonus in adult Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Action myoclonus in adult Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Inhibitors of GABA metabolism: Implications for Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Sodium valproate in Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Valproate Sodium in Huntington Chorea

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Intention myoclonus in Huntington's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Sodium valproate in huntington's chorea

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Sodium valproate in chorea

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Huntington's disease: Treatment with dipropylacetic acid and gamma-aminobutyric acid

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

Juvenile Huntington disease in the Netherlands

20 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Adult onset myoclonic Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Cortical myoclonus in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Improvement of Huntington's disease with olanzapine and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Unified Huntington's disease rating scale: a follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Assessment of complex movements reflects dysfunction in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Clinical markers of early disease in persons near onset of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Bradykinesia in early Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Benefit of valproic acid in suppressing disease progression of ALS model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Neuroprotective properties of valproate: potential benefit for AD and tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-6-11

Congruent deterioration of complex and simple movements in patients with Huntington's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1413552

26 November 2018

Identifiers

DOI

10.1186/1471-2377-6-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 January 2020

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-2377-6-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16507108%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

16507108

1 reference